Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Reviewrac-CCT 250863
说明： Potent Nek2 inhibitor
化学名： 4-[2-Amino-5-[4-[(dimethylamino)methyl]-2-thienyl]-3-pyridinyl]-2-[[(2Z)-4,4,4-trifluoro-1-methyl-2-buten-1-yl]oxy]benzamide
纯度： ≥98% (HPLC)
生物活性 for rac-CCT 250863
rac-CCT 250863 is a potent Nek2 inhibitor (IC50 = 73 nM). Exhibits selectivity for Nek2 over PLK1, MPS1, Cdk2 and Aurora A.
技术数据 for rac-CCT 250863
| 分子量 | 490.54 |
| 公式 | C24H25F3N4O2S |
| 储存 | Store at -20°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 1364269-06-6 |
| PubChem ID | 57386035 |
| InChI Key | LLEOOSLUHRQCHZ-SREVYHEPSA-N |
| Smiles | CN(C)CC1=CSC(C2=CN=C(N)C(C3=CC(OC(/C=C\C(F)(F)F)C)=C(C(N)=O)C=C3)=C2)=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for rac-CCT 250863
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| 1eq. HCl | 49.05 | 100 | |
| DMSO | 49.05 | 100 |
制备储备液 for rac-CCT 250863
以下数据基于产品分子量 490.54。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.04 mL | 10.19 mL | 20.39 mL |
| 5 mM | 0.41 mL | 2.04 mL | 4.08 mL |
| 10 mM | 0.2 mL | 1.02 mL | 2.04 mL |
| 50 mM | 0.04 mL | 0.2 mL | 0.41 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for rac-CCT 250863
参考文献 for rac-CCT 250863
参考文献是支持产品生物活性的出版物。
Innocenti et al (2012) Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity. J.Med.Chem. 55 3228 PMID: 22404346
If you know of a relevant reference for rac-CCT 250863, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: rac-CCT 250863, rac-CCT 250863 supplier, rac-CCT250863, potent, NEK2, inhibitors, inhibits, selective, never-in-mitosis-gene-a-related, kinases, Nek2, Kinase, 4546, Tocris Bioscience
篇 rac-CCT 250863 的引用文献
引用文献是使用了 Tocris 产品的出版物。
目前没有 rac-CCT 250863 的引用文献。 您是否知道使用了 Tocris rac-CCT 250863 的优秀论文？ 请告知我们.
rac-CCT 250863 的评论
目前没有该产品的评论。 Be the first to review rac-CCT 250863 and earn rewards!
Have you used rac-CCT 250863?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Angiogenesis in Cancer Poster
This poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
Cell Cycle & DNA Damage Repair Poster
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.